Literature DB >> 3582487

In vitro and ex vivo effects of indobufen on red blood cell deformability.

S Grasselli, R Guerciolini, V Iadevaia, P Parise, P Gresele, G G Nenci.   

Abstract

We have studied the effect of indobufen, a cyclo-oxygenase blocking agent which has proved useful in patients with obstructive vascular disease, on red blood cell (RBC) filterability in vitro and in a pilot study ex vivo. The addition of indobufen in vitro to blood samples from 10 healthy volunteers did not significantly modify RBC deformability. We evaluated the ex vivo effect of indobufen (200 mg bd) in 14 patients with obstructive vascular disease. A significant improvement in RBC deformability was noted on the 5th, 14th, and 28th days of treatment, 2 h after the morning dose. Acetylsalicylic acid given to 6 similar patients had no effect suggesting that the positive haemorheological effect of indobufen is probably not linked to its cyclooxygenase blocking effect.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3582487     DOI: 10.1007/bf00542198

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  A simple method for measuring erythrocyte deformability.

Authors:  H L Reid; A J Barnes; P J Lock; J A Dormandy; T L Dormandy
Journal:  J Clin Pathol       Date:  1976-09       Impact factor: 3.411

2.  Haemorrheological response to plasma exchange in Raynaud's syndrome.

Authors:  A J Dodds; M J O'Reilly; C J Yates; L T Cotton; P T Flute; J A Dormandy
Journal:  Br Med J       Date:  1979-11-10

3.  Prostaglandin I2 fails to influence red cell deformability.

Authors:  J H Slott; K Hall; D A Clark; M J Stuart
Journal:  Prostaglandins Leukot Med       Date:  1982-01

4.  The effect of malonyldialdehyde on erythrocyte deformability.

Authors:  C Pfafferott; H J Meiselman; P Hochstein
Journal:  Blood       Date:  1982-01       Impact factor: 22.113

Review 5.  Sickle cell anemia as a rheologic disease.

Authors:  M K Horne
Journal:  Am J Med       Date:  1981-02       Impact factor: 4.965

6.  Impaired red cell deformability in peripheral vascular disease.

Authors:  H L Reid; J A Dormandy; A J Barnes; P J Lock; T L Dormandy
Journal:  Lancet       Date:  1976-03-27       Impact factor: 79.321

7.  Inhibition of platelet aggregation in man by indobufen (K 3920).

Authors:  A Vittoria; F Laghi Pasini; G L Messa; T Di Perri; G Corvi; L M Fuccella
Journal:  J Int Med Res       Date:  1981       Impact factor: 1.671

8.  Indobufen (K 3920), a new inhibitor of platelet aggregation: effect of food on bioavailability, pharmacokinetic and pharmacodynamic study during repeated oral administration to man.

Authors:  V Tamassia; G Corvi; L M Fuccella; E Moro; G Tosolini; E Tremoli
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

9.  Dipyridamole increases red cell deformability.

Authors:  S O Sowemimo-Coker; I B Kovacs; H Pickles; A Hedges; P Turner
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

10.  Blood filtrability in cerebrovascular disorders, with special reference to erythrocyte deformability and ATP content.

Authors:  S Sakuta
Journal:  Stroke       Date:  1981 Nov-Dec       Impact factor: 7.914

View more
  2 in total

Review 1.  Indobufen: an updated review of its use in the management of atherothrombosis.

Authors:  N Bhana; K J McClellan
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

2.  Anticoagulant Activities of Indobufen, an Antiplatelet Drug.

Authors:  Jia Liu; Dan Xu; Nian Xia; Kai Hou; Shijie Chen; Yu Wang; Yunman Li
Journal:  Molecules       Date:  2018-06-15       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.